Search research articles
Contact Us
Filters
Showing results (51-60 of 117) with videos related to
Page
of 12
Sort By:
European Journal of Haematology
|
January 8, 2025
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial
Paul Richardson, Meral Beksaç, Albert Oriol, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 16, 2011
Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma
K Jack Ishak, J Jaime Caro, Mark T Drayson, et al.
Seminars in Hematology
|
April 26, 2023
Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis
Giampaolo Merlini, Shayna Sarosiek, Giulia Benevolo, et al.
Critical Reviews in Oncology/Hematology
|
March 18, 2011
Consensus on the utility of bone markers in the malignant bone disease setting
Robert Coleman, Luis Costa, Fred Saad, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
Albert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.
Blood
|
March 2, 2019
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
Thierry Facon, Jae Hoon Lee, Philippe Moreau, et al.
Molecular Biology Reports
|
October 16, 2012
HTERT MNS16A polymorphism in breast cancer: a case-control study
Flora Zagouri, Theodoros N Sergentanis, Maria Gazouli, et al.
Molecular Biology Reports
|
October 16, 2012
HSP90, HSPA8, HIF-1 alpha and HSP70-2 polymorphisms in breast cancer: a case-control study
Flora Zagouri, Theodoros N Sergentanis, Maria Gazouli, et al.
Transplantation and Cellular Therapy
|
November 13, 2022
Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation
Thomas G Martin, Marcelo Capra, Mohamad Mohty, et al.
Leukemia & Lymphoma
|
October 28, 2020
Efficacy and safety of weekly carfilzomib (70 mg/m<sup>2</sup>), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies
Xavier Leleu, Meral Beksac, Takaaki Chou, et al.
Page
of 12
Search research articles
Search
Showing results (51-60 of 117) with videos related to
Sort By:
Page
of 12
European Journal of Haematology
|
January 8, 2025
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial
Paul Richardson, Meral Beksaç, Albert Oriol, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 16, 2011
Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma
K Jack Ishak, J Jaime Caro, Mark T Drayson, et al.
Seminars in Hematology
|
April 26, 2023
Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis
Giampaolo Merlini, Shayna Sarosiek, Giulia Benevolo, et al.
Critical Reviews in Oncology/Hematology
|
March 18, 2011
Consensus on the utility of bone markers in the malignant bone disease setting
Robert Coleman, Luis Costa, Fred Saad, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
Albert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.
Blood
|
March 2, 2019
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
Thierry Facon, Jae Hoon Lee, Philippe Moreau, et al.
Molecular Biology Reports
|
October 16, 2012
HTERT MNS16A polymorphism in breast cancer: a case-control study
Flora Zagouri, Theodoros N Sergentanis, Maria Gazouli, et al.
Molecular Biology Reports
|
October 16, 2012
HSP90, HSPA8, HIF-1 alpha and HSP70-2 polymorphisms in breast cancer: a case-control study
Flora Zagouri, Theodoros N Sergentanis, Maria Gazouli, et al.
Transplantation and Cellular Therapy
|
November 13, 2022
Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation
Thomas G Martin, Marcelo Capra, Mohamad Mohty, et al.
Leukemia & Lymphoma
|
October 28, 2020
Efficacy and safety of weekly carfilzomib (70 mg/m<sup>2</sup>), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies
Xavier Leleu, Meral Beksac, Takaaki Chou, et al.
Page
of 12